(Q35172260)

6 August 2017

1 reference

title

Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs (English)

1 reference

6 August 2017

2

Emilio Perucca

1 reference

6 August 2017

Philip N Patsalos

1

1 reference

6 August 2017

1 June 2003

1 reference

6 August 2017

1 reference

6 August 2017

2

1 reference

6 August 2017

347-356

1 reference

6 August 2017

6

1 reference

The management of epilepsy in the 1990s. Acquisitions, uncertainties and priorities for future research

6 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900409-5

7 January 2021

The importance of drug interactions in epilepsy therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900409-5

7 January 2021

Phenobarbitone to gabapentin: a guide to 82 years of anti-epileptic drug pharmacokinetic interactions

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900409-5

7 January 2021

Antiepileptic drugs. A review of clinically significant drug interactions.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900409-5

7 January 2021

Interference of oral phenytoin absorption by continuous nasogastric feedings

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900409-5

7 January 2021

Phenytoin and nasogastric feedings

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900409-5

7 January 2021

Role of P-glycoprotein in pharmacokinetics: clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900409-5

7 January 2021

Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900409-5

7 January 2021

Relevance of p-glycoprotein for the enteral absorption of cyclosporin A: in vitro-in vivo correlation

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900409-5

7 January 2021

Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900409-5

7 January 2021

Coadministration of cyclosporine strongly enhances the oral bioavailability of docetaxel

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900409-5

7 January 2021

P-glycoprotein and multidrug resistance-associated protein are involved in the regulation of extracellular levels of the major antiepileptic drug carbamazepine in the brain

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900409-5

7 January 2021

Limbic seizures induce P-glycoprotein in rodent brain: functional implications for pharmacoresistance.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900409-5

7 January 2021

Multidrug resistance-associated protein is involved in the regulation of extracellular levels of phenytoin in the brain

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900409-5

7 January 2021

P-Glycoprotein-mediated efflux of phenobarbital, lamotrigine, and felbamate at the blood-brain barrier: evidence from microdialysis experiments in rats

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900409-5

7 January 2021

Mechanisms of antiepileptic drug resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900409-5

7 January 2021

Effect of P-glycoprotein on the pharmacokinetics and tissue distribution of enaminone anticonvulsants: analysis by population and physiological approaches

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900409-5

7 January 2021

Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900409-5

7 January 2021

P-glycoprotein system as a determinant of drug interactions: the case of digoxin-verapamil

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900409-5

7 January 2021

Clinical pharmacology and therapeutic use of the new antiepileptic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900409-5

7 January 2021

In vitro approaches to predicting drug interactions in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900409-5

7 January 2021

Plasma protein binding displacement interactions--why are they still regarded as clinically important?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900409-5

7 January 2021

What is the true clinical significance of plasma protein binding displacement interactions?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900409-5

7 January 2021

Changes in plasma protein binding have little clinical relevance

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900409-5

7 January 2021

Interaction between phenytoin and valproic acid: plasma protein binding and metabolic effects

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900409-5

7 January 2021

Effect of sodium valproate on plasma protein binding of diphenylhydantoin

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900409-5

7 January 2021

Effect of valproate on free plasma phenytoin concentrations

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900409-5

7 January 2021

In vitro hydroxylation of diphenylhydantoin and its inhibition by other commonly used anticonvulsant drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900409-5

7 January 2021

Time-dependent interaction between phenytoin and valproic acid

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900409-5

7 January 2021

A mechanistic approach to antiepileptic drug interactions

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900409-5

7 January 2021

A comparative study of the relative enzyme inducing properties of anticonvulsant drugs in epileptic patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900409-5

7 January 2021

Clinical implications of hepatic microsomal enzyme induction by antiepileptic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900409-5

7 January 2021

Effect of the removal of individual antiepileptic drugs on antipyrine kinetics, in patients taking polytherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900409-5

7 January 2021

Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900409-5

7 January 2021

Drug interactions at the renal level. Implications for drug development

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900409-5

7 January 2021

Oxcarbazepine placebo-controlled, dose-ranging trial in refractory partial epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900409-5

7 January 2021

Children versus adults: pharmacokinetic and adverse-effect differences

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900409-5

7 January 2021

Clinical pharmacokinetics in newborns and infants. Age-related differences and therapeutic implications

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900409-5

7 January 2021

Developmental Aspects of Drug Conjugation, with Special Reference to Glucuronidation

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900409-5

7 January 2021

Valproic acid dosages necessary to maintain therapeutic concentrations in children

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900409-5

7 January 2021

Pharmacokinetics of valproic acid in children: I. Multiple antiepileptic drug therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900409-5

7 January 2021

Liver function and phase I drug metabolism in the elderly: a paradox

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900409-5

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900409-5

7 January 2021

Reduced induction of drug metabolism in the elderly

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900409-5

7 January 2021

Perceptions of differences between pairs of tablets

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900409-5

7 January 2021

Serum carbamazepine concentrations in elderly patients: a case-matched pharmacokinetic evaluation based on therapeutic drug monitoring data

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900409-5

7 January 2021

Pharmacokinetic optimisation of drug therapy in elderly patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900409-5

7 January 2021

Harnessing the clinical potential of antiepileptic drug therapy: dosage optimisation

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900409-5

7 January 2021

Serum concentrations of valproic acid: influence of dose and comedication

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900409-5

7 January 2021

Disposition of sodium valproate in epileptic patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900409-5

7 January 2021

Valproate unbound fraction and distribution volume following rapid infusions in patients with epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900409-5

7 January 2021

Population analysis of the pharmacokinetics of tiagabine in patients with epilepsy.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900409-5

7 January 2021

Effect of enzyme inducing anticonvulsants on ethosuximide pharmacokinetics in epileptic patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900409-5

7 January 2021

Serum concentrations of lamotrigine in epileptic patients: the influence of dose and comedication.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900409-5

7 January 2021

The influence of dosage, age, and comedication on steady state plasma lamotrigine concentrations in epileptic children: a prospective study with preliminary assessment of correlations with clinical response

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900409-5

7 January 2021

Lamotrigine serum concentration-to-dose ratio: influence of age and concomitant antiepileptic drugs and dosage implications

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900409-5

7 January 2021

Comparative pharmacokinetics of zonisamide (CI-912) in epileptic patients on carbamazepine or phenytoin monotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900409-5

7 January 2021

The pharmacokinetics of oxcarbazepine and its active metabolite 10-hydroxy-carbazepine in healthy subjects and in epileptic patients treated with phenobarbitone or valproic acid

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900409-5

7 January 2021

Discontinuation of phenytoin and carbamazepine in patients receiving felbamate

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900409-5

7 January 2021

Influence of phenytoin and phenobarbital on the disposition of a single oral dose of clonazepam

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900409-5

7 January 2021

Concentration of carbamazepine (Tegretol) in serum and in cerebrospinal fluid in patients with epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900409-5

7 January 2021

Influence of phenobarbital and diphenylhydantoin on plasma carbamazepine levels in patients with epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900409-5

7 January 2021

Minor additive inducing effects of phenobarbital on carbamazepine clearance in patients on combined carbamazepine-phenytoin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900409-5

7 January 2021

Influence of oxcarbazepine and methsuximide on lamotrigine concentrations in epileptic patients with and without valproic acid comedication: results of a retrospective study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900409-5

7 January 2021

Methsuximide lowers lamotrigine blood levels: A pharmacokinetic antiepileptic drug interaction

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900409-5

7 January 2021

Primidone kinetics: effects of concurrent drugs and duration of therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900409-5

7 January 2021

Associations Between Risk Factors for Valproate Hepatotoxicity and Altered Valproate Metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900409-5

7 January 2021

Is there a role for therapeutic drug monitoring of new anticonvulsants?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900409-5

7 January 2021

Lack of interaction of gabapentin with carbamazepine or valproate

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900409-5

7 January 2021

Pharmacokinetic profile of levetiracetam: toward ideal characteristics

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900409-5

7 January 2021

Pharmacokinetics of tiagabine, a gamma-aminobutyric acid-uptake inhibitor, in healthy subjects after single and multiple doses

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900409-5

7 January 2021

Lack of an effect of topiramate on lamotrigine serum concentrations

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900409-5

7 January 2021

Effect of felbamate on plasma levels of carbamazepine and its metabolites

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900409-5

7 January 2021

Interaction between vigabatrin and phenytoin

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900409-5

7 January 2021

Vigabatrin does not affect the intestinal absorption of phenytoin in rat duodeno-jejunal loops in situ

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900409-5

7 January 2021

Vigabatrin-induced decrease in serum phenytoin concentration does not involve a change in phenytoin bioavailability.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900409-5

7 January 2021

Mechanism of valproate-phenobarbital interaction in epileptic patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900409-5

7 January 2021

Sodium valproate acutely inhibits lamotrigine metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900409-5

7 January 2021

Acute effects of lamotrigine (BW430C) in persons with epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900409-5

7 January 2021

Lack of an effect of valproate concentration on lamotrigine pharmacokinetics in developmentally disabled patients with epilepsy.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900409-5

7 January 2021

Valproic acid and diazepam interaction in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900409-5

7 January 2021

Effect of valproate on the pharmacokinetics and pharmacodynamics of lorazepam

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900409-5

7 January 2021

Interaction of carbamazepine-10,11-epoxide, an active metabolite of carbamazepine, with valproate: a pharmacokinetic study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900409-5

7 January 2021

Variability and clinical relevance of the interaction between sodium valproate and carbamazepine in epileptic patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900409-5

7 January 2021

Serum concentrations of carbamazepine and its epoxide and diol metabolites in epileptic patients: the influence of dose and comedication

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900409-5

7 January 2021

Sodium valproate and valpromide: differential interactions with carbamazepine in epileptic patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900409-5

7 January 2021

The effects of phenytoin on phenobarbitone and primidone metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900409-5

7 January 2021

Drug Interactions During Anticonvulsant Therapy in Childhood: Diphenylhydantoin, Primidone, Phenobarbitone, Clonazepam, Nitrazepam, Carbamazepin and Dipropylacetate

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900409-5

7 January 2021

Carbamazepine and oxcarbazepine decrease phenytoin metabolism through inhibition of CYP2C19.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900409-5

7 January 2021

Topiramate and phenytoin pharmacokinetics during repetitive monotherapy and combination therapy to epileptic patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900409-5

7 January 2021

Effect of felbamate on phenytoin and carbamazepine serum concentrations

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900409-5

7 January 2021

The effect of felbamate on valproic acid disposition

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900409-5

7 January 2021

Effects of felbamate on the pharmacokinetics of phenobarbital

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900409-5

7 January 2021

Effect of felbamate on clobazam and its metabolite kinetics in patients with epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900409-5

7 January 2021

Inhibition of phenytoin metabolism by sulthiame in epileptic patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900409-5

7 January 2021

Selection of antiepileptic drug polytherapy based on mechanisms of action: the evidence reviewed

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900409-5

7 January 2021

Valproate-ethosuximide combination therapy for refractory absence seizures

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900409-5

7 January 2021

The efficacy of valproate-lamotrigine comedication in refractory complex partial seizures: evidence for a pharmacodynamic interaction.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900409-5

7 January 2021

Lamotrigine as an add-on drug in typical absence seizures

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900409-5

7 January 2021

Lamotrigine substitution study: evidence for synergism with sodium valproate? 105 Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900409-5

7 January 2021

Therapeutic interaction of lamotrigine and sodium valproate in intractable myoclonic epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900409-5

7 January 2021

Disabling tremor after lamotrigine with sodium valproate

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900409-5

7 January 2021

Complex partial seizures: EEG foci and response to carbamazepine and sodium valproate

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900409-5

7 January 2021

Double-blind substitution of vigabatrin and valproate in carbamazepine-resistant partial epilepsy. 012 Study group.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900409-5

7 January 2021

Valproate and clonazepam comedication in patients with intractable epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900409-5

7 January 2021

Vigabatrin and lamotrigine in refractory epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900409-5

7 January 2021

Lamotrigine and topiramate may be a useful combination

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900409-5

7 January 2021

Synergism with GABAergic drugs in refractory epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900409-5

7 January 2021

Reduction in polypharmacy for epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900409-5

7 January 2021

Overtreatment in epilepsy: adverse consequences and mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900409-5

7 January 2021

Antiepileptic drugs as a cause of worsening seizures

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900409-5

7 January 2021

Carbamazepine toxicity with lamotrigine: pharmacokinetic or pharmacodynamic interaction?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900409-5

7 January 2021

Stupor Following Administration of Valproic Acid to Patients Receiving Other Antiepileptic Drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900409-5

7 January 2021

10.1016/S1474-4422(03)00409-5

Identifiers

DOI

1 reference

6 August 2017

1 reference

PubMed ID

12849151